Evidence map›Paper›PMID 27100275›Full record

Trial reportDiabetic medicine : a journal of the British Diabetic Association2016

Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic.

S V Hope, B A Knight, B M Shields, A T Hattersley, T J McDonald, A G Jones

Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in Diabetic medicine : a journal of the British Diabetic Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03369821 (Understanding Beta-cell Destruction Through the Study of EXtremely Early-onset Type 1 Diabetes), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03369821 recruitingnot on this mapstarted 2017, after this paper: background citation

Understanding Beta-cell Destruction Through the Study of EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)

TypeobservationalSponsorUniversity of ExeterRan2017 to 2028Enrolled300ConditionsType1 Diabetes MellitusArmsBeta Cell Loss and Immune Function, Immune Function with RNAseq
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. The evolution of C-peptide's role in diabetes care.Current opinion in endocrinology, diabetes, and obesity · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Exploring the potential role of C-peptide in type 2 diabetes management.Diabetic medicine : a journal of the British Diabetic Association · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Diabetes Study of Children of Diverse Ethnicity and Race: Study design.Diabetes/metabolism research and reviews · 2024
    Observational
  15. Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Article
  16. Article
  17. Fasting and meal-stimulated serum C-peptide in long-standing type 1 diabetes mellitus.Diabetic medicine : a journal of the British Diabetic Association · 2023
    Article
  18. Article
  19. Article
  20. Prospective associations of hemoglobin ACancer research communications · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

S V HopeNIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK.
B A KnightNIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK.
B M ShieldsNIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK.
A T HattersleyNIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK.
T J McDonaldNIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK.
A G JonesNIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK. Angus.Jones@exeter.ac.uk.
University of Exeter · GBNIHR Exeter Clinical Research Facility · GBRoyal Devon & Exeter NHS Foundation Trust · GB

Funding

Department of Health DRF-2010-03-72Department of Health NIHR-HCS-P12-03-03Wellcome Trust
6 · The paper itself

Abstract

backgroundMeasuring endogenous insulin secretion using C-peptide can assist diabetes management, but standard stimulation tests are impractical for clinical use. Random non-fasting C-peptide assessment would allow testing when a patient is seen in clinic.

methodsWe compared C-peptide at 90 min in the mixed meal tolerance test (sCP) with random non-fasting blood C-peptide (rCP) and random non-fasting urine C-peptide creatinine ratio (rUCPCR) in 41 participants with insulin-treated diabetes [median age 72 (interquartile range 68-78); diabetes duration 21 (14-31) years]. We assessed sensitivity and specificity for previously reported optimal mixed meal test thresholds for severe insulin deficiency (sCP < 200 pmol//l) and Type 1 diabetes/inability to withdraw insulin (< 600 pmol//l), and assessed the impact of concurrent glucose.

resultsrCP and sCP levels were similar (median 546 and 487 pmol//l, P = 0.92). rCP was highly correlated with sCP, r = 0.91, P < 0.0001, improving to r = 0.96 when excluding samples with concurrent glucose < 8 mmol//l. An rCP cut-off of 200 pmol//l gave 100% sensitivity and 93% specificity for detecting severe insulin deficiency, with area under the receiver operating characteristic curve of 0.99. rCP < 600 pmol//l gave 87% sensitivity and 83% specificity to detect sCP < 600 pmol//l. Specificity improved to 100% when excluding samples with concurrent glucose < 8 mmol//l. rUCPCR (0.52 nmol/mmol) was also well-correlated with sCP, r = 0.82, P < 0.0001. A rUCPCR cut-off of < 0.2 nmol/ mmol gave sensitivity and specificity of 83% and 93% to detect severe insulin deficiency, with area under the receiver operating characteristic curve of 0.98.

conclusionsRandom non-fasting C-peptide measures are strongly correlated with mixed meal C-peptide, and have high sensitivity and specificity for identifying clinically relevant thresholds. These tests allow assessment of C-peptide at the point patients are seen for clinical care.

Indexed as

Diagnostic Techniques, EndocrineAgedClinical Laboratory TechniquesC-PeptideDiabetes Mellitus, Type 1FastingFemaleGlucose Tolerance TestHumansInsulinInsulin SecretionMaleMealsC-PeptideInsulin

Identifiers

PMID27100275
PMCPMC5226330
OpenAlexW2341387423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.